Next Article in Journal
Performance of the LIAISON® SARS-CoV-2 Antigen Assay vs. SARS-CoV-2-RT-PCR
Previous Article in Journal
Comparative Assessment of In-House Real-Time PCRs Targeting Enteric Disease-Associated Microsporidia in Human Stool Samples
Article

Serial Interferon-Gamma Release Assay (IGRA) Testing to Monitor Treatment Responses in Cases of Feline Mycobacteriosis

1
The Royal (Dick) School of Veterinary Studies and The Roslin Institute, Easter Bush Campus, University of Edinburgh, Midlothian EH25 9RG, UK
2
Biobest Laboratories Ltd., Edinburgh Technopole, Milton Bridge EH26 0PY, UK
*
Author to whom correspondence should be addressed.
Current address: Perth Vets4Pets, Inside Pets at Home, St. Catherine’s Retail Park, St Catherine’s Road, Perth PH1 5XD, UK.
Current address: White Lodge Veterinary Surgery, 207 Exeter Road, Exmouth EX8 3DZ, UK.
§
These authors have joint credit as final author.
Academic Editor: Vito Martella
Pathogens 2021, 10(6), 657; https://doi.org/10.3390/pathogens10060657
Received: 5 May 2021 / Revised: 24 May 2021 / Accepted: 25 May 2021 / Published: 26 May 2021
The interferon-gamma release assay (IGRA) is used to diagnose cases of feline mycobacteriosis, but the use of serial testing to monitor treatment responses has not been evaluated in this species. From a population of cats that underwent IGRA testing for diagnostic investigation, individuals were identified with a pre- and end-of-treatment IGRA that passed control thresholds. The number of cats which reverted to negative at the end-of-treatment IGRA, changes in paired antigen-specific optical density (OD) values and differences in the pre-treatment antigen-specific OD values for those which underwent reversion were compared. Factors to explain reversion or recurrence of disease post-treatment were explored. Four of 18 cats (22%) reverted to negativity at the point of clinical resolution (p = 0.33), there was no difference in paired antigen-specific OD values (p ≥ 0.12), and cats that reverted did not have a lower baseline OD value (p = 0.63). No statistically significant factors were identified to predict reversion (p ≥ 0.08). Remaining positive at the end of treatment IGRA was not associated with recurrence of disease post-treatment (p = 0.34). Overall, these data suggest there is limited value in the use of the IGRA to monitor treatment responses in cats. View Full-Text
Keywords: cat; tuberculosis; mycobacteria; monitoring; interferon-gamma release assay; diagnostics cat; tuberculosis; mycobacteria; monitoring; interferon-gamma release assay; diagnostics
Show Figures

Figure 1

MDPI and ACS Style

Mitchell, J.L.; O’Halloran, C.; Stanley, P.; McDonald, K.; Burr, P.; Gunn-Moore, D.A.; Hope, J.C. Serial Interferon-Gamma Release Assay (IGRA) Testing to Monitor Treatment Responses in Cases of Feline Mycobacteriosis. Pathogens 2021, 10, 657. https://doi.org/10.3390/pathogens10060657

AMA Style

Mitchell JL, O’Halloran C, Stanley P, McDonald K, Burr P, Gunn-Moore DA, Hope JC. Serial Interferon-Gamma Release Assay (IGRA) Testing to Monitor Treatment Responses in Cases of Feline Mycobacteriosis. Pathogens. 2021; 10(6):657. https://doi.org/10.3390/pathogens10060657

Chicago/Turabian Style

Mitchell, Jordan L., Conor O’Halloran, Paul Stanley, Kieran McDonald, Paul Burr, Danièlle A. Gunn-Moore, and Jayne C. Hope 2021. "Serial Interferon-Gamma Release Assay (IGRA) Testing to Monitor Treatment Responses in Cases of Feline Mycobacteriosis" Pathogens 10, no. 6: 657. https://doi.org/10.3390/pathogens10060657

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop